KRAS and neoplasm: In this context, miRNAs inhibiting expression of PTEN (miR-425 and miR-148a) should be considered as oncomirs, and those inhibiting KRAS, EGFR, PIK3CA, TGFBR1, and SMAD2 (let-7g, miR-150, miR-128, miR-139, miR-148a, miR-148b) as tumor suppressors.